Dave Malenfant

LogiPharma USA 2025: Pharma Supply Chains Evolve Toward Real-Time Visibility and End-to-End Control

 Editor Nico Saraceno spoke with several key opinion leaders about how technology, innovation, and inclusivity are reshaping pharmaceutical logistics.

Krenar Komoni, founder and CEO of Tive, highlighted a critical industry shift: the move from passive to real-time temperature control. While adoption has been slower than anticipated, Komoni noted that progress is accelerating, aided by new technologies. He predicted that the full transition to real-time visibility could take another 12 to 36 months, citing the challenges of scaling across global networks.

McKesson’s Ammie McAsey, SVP of supply chain operations, discussed how advanced therapies are challenging traditional distribution models. Precision medicines and individualized treatments require a new level of quality assurance and communication across stakeholders. McAsey emphasized investments in both physical infrastructure, including refrigeration, frozen, and cryogenic systems, and digital platforms that enable seamless communication between providers and manufacturers. As she explained, distributors like McKesson play a key role in bridging these operational and technological gaps.

Finally, healthcare supply chain expert Dave Malenfant reflected on LogiPharma’s evolution over the past two decades, noting the conference’s growing inclusivity and representation. Once a male-dominated space, today’s event features diverse voices and a mix of companies spanning clinical and commercial supply chain disciplines.

Together, these insights underscore a unifying theme: pharma supply chains are becoming more connected, data-driven, and people-focused than ever before.

A transcript of their conversation of their conversation can be found below.

 Welcome to a special edition of LogiPharma USA coverage. I’m Nico Saraceno, editor of 

. This year’s installment of the conference was yet another action-packed one, as I had the opportunity to speak with a variety of KOLs in the space, including Krenar Komoni, founder and CEO of Tive, who highlighted the transition in pharma from passive to real-time temperature control.

How did he do that? He noted delays in tech adoption while emphasizing how AI and automation will soon drive cost savings, improved quality, and stronger customer experience.

 What challenges are currently impacting the temperature-controlled space?

 So the temperature control space and all the various companies, especially in the pharmaceutical side, they're going through a transition phase, which I call it, going from passive to real time. And it's taking its time. And I wish we were there sooner, but there's a lot of reasons why we're not there yet.

Technology providers haven't moved as fast we're finally just for instance, with dive, we released a solo pro device, which is a pharma specific real time tracker that meets all the 21 CFR Part 11 requirements. It's GXP compliant. And to be able to move everything from passive to real time, it's gonna take a little bit longer time. Call it another 12 months, maybe 24 to 36 months max. But this is one of the challenges right now, is this transition, and what comes with this transition.

Now when I asked Ammie McAsey, McKesson’s SVP of Supply Chain Ops, how advanced therapies are challenging traditional supply chain models, she dove into the need for end-to-end visibility among other qualities.

 Challenging the traditional supply chain model, traditional kind of pharma has been—in the distributor space—built for speed and efficiency, and while that's critically important, quality is of the utmost importance. The supply chain seems to be a little bit longer and has a lot more partners as we think about the precision medicine, and potentially one therapy for one cure and one patient.

The investment in technology to ensure end-to-end visibility and end-to-end communication is really, really important, so that's challenging the model. There are also temperature challenges, vibration challenges, multiple other scenarios that we have to account for with these specialized drugs.

How are we addressing that? Really around investments, and we have to look again across the supply chain for those investments, whether it's in refrigeration, in frozen, in cryo, or whether it's digital investments that allow for that visibility and tracking and communication between the provider, as well as the manufacturer of the drug or the therapy. You have to hit it from both angles, but I think as we sit in the middle as a distributor, we're well positioned to do both.

 Let us not forget Dave Malenfant, a healthcare supply chain expert, who took us through LogiPharma USA’s development over the past two decades.

 When LogiPharma first came out, there were not a lot of women, and it was a very male dominated industry. And we've evolved where, if you notice the crowd now, a lot of women. Finally, we've got a lot of women that are coming into the industry, WBR and LogiPharma has done a really good job of trying to embrace as many different companies, small, medium, large, and in folks that are really concentrated on both the clinical side and on the commercial side of supply chain.

Videos

At LogiPharma USA, industry leaders from Tive, McKesson, and the broader healthcare logistics community discussed the sector’s transition from passive monitoring to real-time control, the growing influence of advanced therapies, and the importance of diversity and innovation in shaping the future of pharma supply chains.

LogiPharma USA 2025: What Were the Standout Trends?

At the 20th anniversary of LogiPharma USA, Dave Malenfant reflected on the event’s growth and its pivotal role in shaping discussions across the pharmaceutical supply chain. With over 700 attendees and standing-room-only master classes, Malenfant emphasized the strong industry engagement and the event’s ability to attract professionals from diverse company sizes and both clinical and commercial supply chain functions.

Looking back over two decades, Malenfant pointed out how the industry and the conference itself have evolved. In the early years, the sector was heavily male dominated, but today, greater female representation is evident across attendees and leadership roles. He credited Logipharma for broadening its reach and relevance, adapting to trends, and becoming, in his view, the premier global conference for pharmaceutical supply chain leaders.

For Malenfant, the continued growth of Logipharma is a testament to its ability to remain timely and relevant, bringing together a community that is both tackling current challenges and preparing for future transformations in supply chain management.

A transcript of Malenfant’s conversation with 

What have been some of the trends that have stood out at this year’s conference?

 AI, artificial intelligence, and how that plays into the whole area of supply chain, the integrated supply chain, the problem with AI. And we have a lot of discussions on AI. We're going to talk, I've got a moderating a panel that's going to talk about digital transformation and AI and but we have to be careful when you have an agenda that's really in a trend like AI, that we don't forget about the people and try and understand that it takes a new organization, A different kind of skill set in order to manage the trend of AI and other technologies that are coming forth. But AI is by far the number one trend that's going to dominate this year, obviously, and it's going to dominate 2026 and I think it's going to dominate through to 2030.

Dave Malenfant, healthcare supply chain expert, outlines the topics that are top of mind at the show.

LogiPharma USA 2025: The Conference's Development Over 20 Years

With LogiPharma USA celebrating 20 years, how have you seen it develop over the years?

When LogiPharma first came out, there were not a lot of women, and it was a very male dominated industry. And we've evolved where, if you notice the crowd now, a lot of women. Finally, we've got a lot of women that are coming into the industry, WBR and LogiPharma has done a really good job of trying to embrace as many different companies, small, medium, large, and in folks that are really concentrated on both the clinical side and on the commercial side of supply chain. And I've seen it grow and then drop off because of Covid. And now this is by far the largest that they've had, and the subject matter the very relevant, the content in the on the agenda is always very relevant for the trends and for the happenings of the time that's coming up. So I think, you know, they've really evolved to becoming, in my opinion, the premier conference for the pharmaceutical industry.

Dave Malenfant, healthcare supply chain expert, reflects on LogiPharma USA’s 20-year evolution, noting its shift toward greater diversity and inclusion, particularly with more women entering the industry.

LogiPharma 2025: Dave Malenfant's Sneak Peek into LogiPharma

You have quite a busy slate here at LogiPharma. Could you offer up a sneak peek of what to expect?

I'm amazed of how many people we've got here. It's over 700 and I know I've been doing these master classes now at LogiPharma and LogiMed for years, and yesterday, my master class was standing room only, which is really encouraging, and it's exciting as well, that that we're having so many people from the industry coming together. I've got the pleasure of managing a track, being the chair of a track which is on people, which is my passion, because, if you notice, the agenda is very heavy, on a lot of technology. And so I have the opportunity of facilitating the track that's going to be on people. We're going to talk about diversity, inclusion and equity. The panelists on that on are very, very well versed in it. We're going to also talk about trade compliance. That's a real hot subject right now, but not enough time to cover everything that needs to come into it. So, it's an exciting event. I'm really, really pleased, especially for the 20th anniversary. 

Dave Malenfant, healthcare supply chain expert, shares his excitement about the strong turnout at LogiPharma USA, noting a packed master class and his role as chair of the “people” track—a personal passion.

Dave Malenfant

Articles